The short answer
As of September 2026, letters from the Food and Drug Administration (FDA) say a research label does not outweigh evidence of intended human drug use.
Purpose matters alongside wording
In those letters, the Food and Drug Administration used the sellers’ own claims about the body to assess the products’ intended use.
The letters are enforcement allegations directed to specific firms, rather than court decisions.
Read the whole offer. What does it claim the product will change? What is included with it? Who is meant to make the treatment decision?
Accessories do not turn an offer into care
As of September 2026, FDA letters also cited mixing water and preparation resources as evidence that products were intended for injection.
A set of supplies can look complete while leaving your injury out of the decision. Ask who would assess you, what product they propose, and how questions would be handled afterward.
Return to an assessment
Bring the product page into a conversation with a clinician. Ask about the claim without treating the page as instructions. Keep the discussion about your injury and the actual preparation being proposed.
- What is the product being offered for?
- Who would assess whether it fits my case?
- What is its current status?
- Who would remain available to answer questions?
Carry this forward
Read a research label as part of the offer, not as evidence that the offer is care.